The finding that vitamin D deficiency was lower in infliximab-treated patients is likely to be explained by more active disease at baseline evidenced by a higher serum CRP and fecal calprotectin observed in infliximab- compared to adalimumab-treated patients in this real-world study. Here, CRP is linked to vitamin D deficiency.